Latest From Biotech Now

We Need Your Input: BIO Survey on Effective FDA-Sponsor Communication

FDA115x76

BIO is surveying members and non-members on their interactions with the FDA during the various stages of drug development prior to submitting an NDA/BLA. The survey can be accessed here. Why is it important for you to share your feedback? In an increasingly competitive and fiscally-constrained environment, it is more important than ever for all stakeholders to work together to promote effective R&D for innovative medicines. In this BIO BuzzCenter video, Alnylam’s Dr. John Maraganore Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , ,

The Perfect Close

72263479

With a fast and furious finish, yesterday, March 2nd, the Nasdaq Composite (IXIC) closed at 5,008.10, marking the third day in history with a close above 5,000. Since 95% of US publicly traded biotech companies are listed on the Nasdaq exchange, the team at BIO couldn’t help but join the excitement. Back in 2000, the Nasdaq index was flourishing with dot coms. At that point there was no Facebook or Netflix and Google wasn’t public. Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , ,

GMO Answers Highlights the Potential of GM Varieties for non-GM Commodity Crops

GMO Answers

Each week in February, GMO Answers highlighted a different commodity crop, its role in agricultural production and its relationship to biotechnology and GMOs. Weeks 1, 2 and 3 looked at corn, soybean and cotton.  Week 4 explored a few commodity crops that are non-GM, including cassava, peanuts and rice, and the potential for GM varieties of these crops. Cassava Cassava is the third largest source of food carbohydrates in the tropics after rice and maize, provides basic sustenance for over half a billion people…According to a study Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

Kyle Bass Files Second IPR Petition

Attribution: Vlad Lazarenko via Wikimedia Commons

Today hedge fund manager Kyle Bass has continued his reported “short activist strategy” campaign by filing a second Inter Partes Review (IPR) petition with the U.S. Patent and Trademark Office (USPTO). BIO expressed grave concerns with this exploitation of the patent challenge system following Mr. Bass’ initial filing earlier this month. Follow the below links to read more. BIO’s prior statement issued following Kyle Bass’ first IPR Petition When The Deck is Stacked Against Innovators, Everyone Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , ,

When The Deck is Stacked Against Innovators, Everyone Loses

US_Patent_And_Trademark_Office

Yesterday, I took part in a series of successful meetings on Capitol Hill regarding the USPTO’s Inter Partes Review system (IPR). Joined by several of BIO’s member companies, we expressed our concerns with how the system is evolving into one which makes it easier for IPR challengers to win than in Federal Court. The implementation of the IPR system – developed through the 2011 America Invests Act – has unintentionally invited abuses of the USPTO Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , ,